Accuray Inc (ARAY)
1.68
+0.08
(+5.00%)
USD |
NASDAQ |
May 15, 14:59
Accuray Accounts Receivable (Quarterly): 73.15M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 73.15M |
December 31, 2023 | 77.40M |
September 30, 2023 | 77.37M |
June 30, 2023 | 74.78M |
March 31, 2023 | 77.35M |
December 31, 2022 | 89.19M |
September 30, 2022 | 77.03M |
June 30, 2022 | 94.44M |
March 31, 2022 | 89.30M |
December 31, 2021 | 81.90M |
September 30, 2021 | 94.04M |
June 30, 2021 | 73.01M |
March 31, 2021 | 69.91M |
December 31, 2020 | 65.37M |
September 30, 2020 | 75.03M |
June 30, 2020 | 78.86M |
March 31, 2020 | 102.68M |
December 31, 2019 | 87.73M |
September 30, 2019 | 104.68M |
June 30, 2019 | 106.62M |
March 31, 2019 | 99.77M |
December 31, 2018 | 86.33M |
September 30, 2018 | 66.42M |
June 30, 2018 | 62.78M |
March 31, 2018 | 81.85M |
Date | Value |
---|---|
December 31, 2017 | 80.91M |
September 30, 2017 | 69.65M |
June 30, 2017 | 69.97M |
March 31, 2017 | 87.09M |
December 31, 2016 | 71.67M |
September 30, 2016 | 56.94M |
June 30, 2016 | 54.15M |
March 31, 2016 | 89.32M |
December 31, 2015 | 66.04M |
September 30, 2015 | 56.64M |
June 30, 2015 | 74.92M |
March 31, 2015 | 61.38M |
December 31, 2014 | 62.99M |
September 30, 2014 | 52.94M |
June 30, 2014 | 71.99M |
March 31, 2014 | 59.26M |
December 31, 2013 | 73.78M |
September 30, 2013 | 59.68M |
June 30, 2013 | 54.67M |
March 31, 2013 | 53.59M |
December 31, 2012 | 63.10M |
September 30, 2012 | 57.39M |
June 30, 2012 | 67.58M |
March 31, 2012 | 72.48M |
December 31, 2011 | 73.93M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
65.37M
Minimum
Dec 2020
106.62M
Maximum
Jun 2019
83.49M
Average
78.13M
Median
Accounts Receivable (Quarterly) Benchmarks
Boston Scientific Corp | 2.304B |
Integer Holdings Corp | 237.15M |
ResMed Inc | 779.26M |
Glaukos Corp | 46.54M |
Perspective Therapeutics Inc | 1.165M |